quizartinib
daiichi sankyo
['quizartinib', 'leusm', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'quantum-first']
congress #eha22 | harry erba presented results from quantum-first phase iii trial of quizartinib in pts ages 18-75 yrs with nd flt3-itd+ aml. n=539. median follow-up=39 months, median os=31.9 months, cr=71.6%, median rfs=39.3 months #leusm 
The AML Hub is an evidence-based online resource on Acute Myeloid Leukemia (AML), for academic researchers and treating clinicians. #leusm